BFM
AMLX icon

Boothbay Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boothbay Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-53,400
Closed -$152K – 1495
2024
Q1 		$152K Buy
+53,400
New +$698K ﹤0.01% 1373
2023
Q4 		– Sell
-100,700
Closed -$1.84M – 1633
2023
Q3 		$1.84M Buy
+100,700
New +$2.13M 0.04% 527

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's AMLX Position: Q1 2025 in Review

Boothbay Fund Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 80,543 shares — an estimated $304K sold.

Boothbay Fund Management first reported a position in AMLX in Q1 2022 and held it in 7 quarters. The position peaked at $3.23M in Q4 2023. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

  • Boothbay Fund Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 80,543 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $304K.
  • Boothbay Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Boothbay Fund Management's Amylyx Pharmaceuticals position peaked at $3.23M in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.